Isoniazid-resistant Disseminated *Mycobacterium Tuberculosis* in a Jamaican Infant with HIV/AIDS

I Singh-Minott¹,², RB Pierre¹,², O Olugbuyi¹,², J Dunkley-Thompson¹, D Haughton³, CDC Christie¹,²

**ABSTRACT**

*A case report of isoniazid-resistant disseminated tuberculosis in a young child perinatally co-infected with human immunodeficiency virus (HIV-1) and the challenges managing this child in a resource-constrained setting.*

**CASE REPORT**

The index case is a 16-month old male child born to an 18-year old primigravida who was diagnosed with HIV infection in the second trimester. She did not receive antiretroviral
therapy or chemoprophylaxis in the antenatal period or during labour. The mother did not disclose her HIV seropositive status to the staff in the labour ward. The infant was born at term via spontaneous vaginal delivery, birthweight 3.17 kgs and received single dose nevirapine at birth. Replacement feeds were provided and the infant subsequently commenced co-trimoxazole for *Pneumocystis jirovecii* (PCP) prophylaxis. The Bacille Calmette Guérin (BCG) vaccine was administered at birth.

At six months of age, he was evaluated in the outpatient department and noted to have oral candidiasis, bronchiolitis and generalized hypertonia. He was admitted to a type B hospital (ie there are no subspecialties available, only medicine, general surgery, obstetrics and gynaecology, and paediatrics) at eight-months old with persistent oropharyngeal candidiasis, bronchopneumonia and gastroenteritis. Re-admission occurred at nine months of age for persistent vomiting and malnutrition. At this time, he was diagnosed with severe HIV/AIDS with CDC category C disease associated with HIV encephalopathy, spastic quadriplegia and global developmental delay. Highly active antiretroviral therapy (HAART) was commenced with zidovudine, lamivudine and nevirapine. HIV-PCR screening test was not yet introduced to Jamaica.

In the two months following initiation of HAART, the infant had four admissions because of recurrent fever, respiratory distress and failure to thrive. He was treated presumptively for PCP pneumonia and acute bacterial infections. Five months after commencing HAART (13 months old), he was re-admitted with recurrent fever and persistent respiratory distress. On examination, he had failure to thrive, generalized lymphadenopathy, hepatosplenomegaly, and right axillary adenitis involving the ipsilateral site of the BCG vaccination.

He was subsequently referred to the University Hospital of the West Indies for further management. The chest radiograph showed a widened mediastinum and the mantoux skin test was negative. Pulmonary TB was confirmed when acid fast bacilli were identified in gastric washings.

First-line quadruple anti-tuberculous (anti-TB) therapy was commenced with rifampicin (RIF), isoniazid (INH), ethambutol (ETH) and pyrazinamide (PZA). Recurrent painful erythematous subcutaneous nodules first presented on the lower limbs but progressed to involve upper limbs and scalp and subsequently drained serosanguinous fluid (Fig. 1). Excision biopsy of the nodules and right axillary lymph node revealed caseating granulomas on histology (Figs. 2, 3). Despite appropriate first line anti-TB therapy with direct observational therapy in hospital and antibiotic coverage for possible bacterial superinfections, he continued to have intermittent pyrexia. The plasma HIV RNA (viral load) assessed five months after HAART initiation was 13 300 copies/ml and the CD4+ was 44%.

Three months after initiating anti-TB therapy, the regional laboratory at the Caribbean Epidemiology Centre (CAREC) reported isolating *M tuberculosis* from the gastric washings, subcutaneous nodules (*tuberculosis cutis*) and the axillary lymph node. The isolate was reported as resistant to isoniazid but susceptible to rifampicin, ethambutol and streptomycin. Sensitivity testing was not reported for pyrazinamide.

In consultation with the Infectious Diseases team, isoniazid was discontinued and the anti-TB regimen revised to include RIF, ETH, PZA with the addition of streptomycin (given intramuscularly) and a fluoroquinolone (ciprofloxacin). Evaluation for other target sites of dissemination (liver, lung, bone, brain, eyes and kidney) was non-contributory.

Public health officials were emergently advised to initiate surveillance for the source of drug-resistant TB infection and to identify any potential contacts.

Contact tracing including mantoux testing was conducted on family members but were reported negative. The probable adult source for this child’s infection has not yet been identified. In addition, all possible in-hospital contacts were screened by mantoux testing and chest radiographs, as indicated. Six months following initiation of the revised anti-TB regime, the young child demonstrated significant weight gain, resolution of cutaneous lesions [*tuberculosis cutis*] (Fig. 4) and his repeat gastric washings were negative for acid fast bacilli and the culture showed no growth.

**DISCUSSION**

Tuberculosis is a leading cause of death amongst HIV-infected individuals worldwide and accounted for 250 000 deaths in 2004 in TB-HIV co-infected populations (9). The emergence of drug-resistant TB has increasingly become a global problem and a threat to TB control (10). This case highlights the challenges faced in diagnosing and managing TB in resource-constrained settings.
Limited laboratory capacity in Jamaica for diagnosis and susceptibility testing for \textit{M. tuberculosis} was a significant barrier to initiating timely specific interventions. The local TB laboratory only offers microscopy reports from direct smears only in the identification of acid fast bacilli. The TB laboratory is not equipped to identify the organism or offer drug susceptibility testing. Furthermore, regarding the clinical progression following HAART initiation, BCG vaccine-induced disease (11), \textit{Mycobacterium bovis} co-infection, drug resistant TB, immune reconstitution syndrome (12, 13) and antiretroviral treatment failure were also considered in the differential diagnoses.

Commercial kits utilizing polymerase chain reaction for detection of \textit{M. tuberculosis} can detect the organism within two hours of testing but these are unavailable in Jamaica. And the recently available interferon-alpha release assays for diagnosis of TB in adults have not yet been validated for use in infants, children and adolescents or immunocompromised individuals (2).

The treatment of drug resistant TB in children is challenging. The second-line drugs are expensive, have an increased toxicity profile and some (eg streptomycin) require parenteral administration. Long-term use of aminoglycosides is associated with nephrotoxicity and ototoxicity (14). Fluoroquinolones are relatively contraindicated in the pediatric age group because of the risk for cartilage abnormalities observed in human testing (15). Although Burkhardt et al reviewed 7000 children between ages 5–24 years who received fluoroquinolones and observed no association between quinolone usage and arthropathy (16). Second-line anti-TB therapy also requires prolonged hospitalization, separation from parents, loss of school time and resultant psychosocial impact of institutionalization.

Data are limited regarding the optimal duration of therapy for drug resistant TB in HIV co-infected children (17–20). A retrospective review of 39 Peruvian children < 15 years of age with multidrug resistant TB demonstrated a 93% cure rate (21). Children were treated with a combination of first and second-line therapy for 18–24 months (for a minimum of 12 consecutive months of negative cultures). Just two of the 39 children were HIV-infected.

In-hospital infection control presented a challenge in this case. Drug resistant TB especially in HIV co-infected individuals requires stringent methods to control cross infection such as confinement to a negative pressure room and other special precautions for nursing. Without appropriate isolation facilities great concern was expressed regarding exposure to healthcare personnel, other patients and visitors to the ward. This child co-infected with HIV and resistant TB had pulmonary TB with disseminated actively draining skin lesions with the potential risk of transmission to contacts in the healthcare setting. Children with HIV and TB co-infection are more likely to transmit TB in the healthcare setting (22). Greater consideration needs to be given for including rooms with air at negative pressure for nursing these patients in future hospital design. In addition, adult community contacts of the patient should be barred from visiting the hospital until they had been screened with a Mantoux skin test and chest radiograph and active tuberculosis had been conclusively excluded. Nosocomial TB needs to be considered and actively investigated at both hospitals where this child was cared for and treated. Of greater concern is the impact of exposure in the community from which this index case was referred and the fact that the probable adult source had not been identified. This case has highlighted the tardiness of contact tracing and that paediatric TB is dependent on prompt diagnosis and treatment of the adult contact as well as appropriate chemoprophylaxis of exposed infants and children.

Directly Observed Treatment Short-course (DOTS) therapy is the current programme used in the therapeutic management of TB in Jamaica. While adherence is assured in the hospital setting, access to and monitoring of continued anti-TB therapy following discharge from hospital are hampered by affordability and availability of the drugs and limited human resource. DOTS therapy constitutes the heart of the Stop TB Strategy (23) and the key components encompass political commitment and sustained financing case detection through quality-assured bacteriology standardized supervised treatment, an effective drug supply and monitoring, evaluation and impact assessment. These criteria challenge the framework of the current programme in Jamaica and raise significant implications for the promotion of multi-drug resistant TB in the setting.

There are critical ‘gaps’ in the pathway of activities leading to effective TB control in our setting. Inadequate numbers of trained personnel for surveillance, contact tracing, laboratory evaluation and monitoring of community-based treatment continue to hinder optimal management of probable cases of TB. Although policies are in place, effective dissemination of information and retraining of new healthcare personnel should be instituted. The deficiencies of laboratory capacity require urgent attention. Alternatively, expedient collaboration with CAREC could be explored in the interim. The Ministry of Health could consider accessing the National Health Fund to enable free access to anti-TB drugs and thus promote adherence while limiting the development of resistance.

Internationally, the World Health Organization (WHO) provides guidance on scaling-up TB control activities through the Global Plan to Stop TB 2006–2015 (23). With the aim to sustain high levels of case detection (at least 70%) and cure (85% treatment success), developing countries have the framework on which to effectively reduce the impact of TB among HIV co-infected populations. However, to achieve this will require political commitment, financial support, effective intervention, patients’ involvement, community participation and ongoing research (24) and development of improved drugs, diagnostics and vaccines.
In conclusion, the goal of managing drug-resistant TB should be focussed on primary prevention and effective treatment. In Jamaica, development of drug resistant TB can be reduced by ensuring appropriately prescribed anti-TB drug dosages, implementing an effective DOTS programme, providing free and amenable access to the drugs, implementing policies and programmes to prevent nosocomial infection and establishing effective monitoring systems. The newer rapid methods for detection of the organism and resistance patterns must be made accessible to developing countries where the burden of TB and HIV are greatest. Controlled trials on effective treatment protocols for HIV-infected children co-infected with tuberculosis are also needed.

REFERENCES